 | Here's a couple of stock ideas I'm looking at for next week. These are companies I'll consider investing in with any funds that become available in my accounts. I believe each of these has a greater potential return than analysts currently expect. As with all of my investments, I'll start with a small position and then add to that position over time through dividend reinvestment, the sale of stock options and direct purchases on the open market. |
RCI Hospitality Holdings, Inc., through its subsidiaries, engages in the hospitality and related businesses in the United States. It operates in two segments, Nightclubs and Bombshells Restaurants/Sports Bars. The company owns and/or operates upscale adult nightclubs serving primarily businessmen and professionals under the Rick's Cabaret, Vivid Cabaret, Tootsie's Cabaret, Club Onyx, Jaguars Club, XTC Cabaret, Hoops Cabaret, Downtown Cabaret, Temptations, Silver City Cabaret, Foxy's Cabaret, Cabaret East, and The Seville brands. It also operates four restaurants/sports bars under the Bombshells brand; and a bar under the Studio 80 brand. As of December 13, 2016, the company operated 41 units that offers live adult entertainment, and/or restaurant and bar operations. In addition, it owns a national industry convention and tradeshow; 2 national industry trade publications; 2 national industry award shows; and approximately 25 industry Websites. The company was formerly known as Rick's Cabaret International, Inc. and changed its name to RCI Hospitality Holdings, Inc. in August 2014. RCI Hospitality Holdings, Inc. was founded in 1982 and is based in Houston, Texas.
(Summary) (Company) (Chart)
(Summary) (Company) (Chart)
| 29 October 2017 Price $27.16 1yr Target $32.50 Analysts 2 Dividend $0.12 Payout Ratio 10.61% 1yr Cap Gain 19.66% Yield 0.44% 1yr Tot Return 20.10% P/E 24.06 PEG 0.60 Beta 0.25 | EPS (ttm) $1.13 EPS next yr $1.91 Forward P/E 14.24 EPS next 5yr 40.00% 1yr Price Support $76.40 Market Cap $258.02 Mil Revenues $138.70 Mil Earnings $10.90 Mil Profit Margin 7.85% Quick Ratio 0.90 Current Ratio 1.00 Debt/Equity 0.92 | 1yr RevGR -0.44% 3yr RevGR 6.25% 5yr RevGR 10.06% 1yr EarnGR 22.22% 3yr EarnGR 4.59% 5yr EarnGR 6.84% 1yr DivGR --- 3yr DivGR --- 5yr DivGR --- ROA 3.80% ROE 8.30% |
Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. The company's products include CABOMETYX for the treatment of patients with advanced renal cell carcinoma, who have received prior anti-angiogenic therapy; and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program. It also offers COTELLIC (cobimetinib), a selective inhibitor of MEK, in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
(Summary) (Company) (Chart)
(Summary) (Company) (Chart)
| 29 October 2017 Price $26.63 1yr Target $32.29 Analysts 7 Dividend $0.00 Payout Ratio 0.00% 1yr Cap Gain 21.25% Yield 0.00% 1yr Tot Return 21.25% P/E 140.90 PEG 3.06 Beta 1.91 | EPS (ttm) $0.19 EPS next yr $0.67 Forward P/E 39.69 EPS next 5yr 46.00% 1yr Price Support $30.82 Market Cap $7.91 Bil Revenues $319.70 Mil Earnings $58.20 Mil Profit Margin 18.20% Quick Ratio 4.10 Current Ratio 4.10 Debt/Equity 0.00 | 1yr RevGR 415.04% 3yr RevGR 81.70% 5yr RevGR -7.95% 1yr EarnGR --- 3yr EarnGR --- 5yr EarnGR --- 1yr DivGR --- 3yr DivGR --- 5yr DivGR --- ROA 10.40% ROE 59.70% |
Vertex Pharmaceuticals Incorporated discovers, develops, manufactures, and commercializes medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene. The company also develops Tezacaftor (VX-661), a corrector compound that is in a Phase III development program in combination with ivacaftor in multiple CF patients; VX-152 and VX-440 that are CFTR corrector compounds in Phase II clinical trials, as well as VX-659 and VX-445 that are CFTR corrector compounds in Phase I clinical trials; and VX-371, an investigational epithelial sodium channel, which is in a Phase II development program. In addition, it engages in the research and mid-and early-stage development programs in the areas of oncology, pain, and neurology. The company sells its products primarily to specialty pharmacy providers and wholesalers in North America, as well as government-owned and supported customers internationally. Vertex Pharmaceuticals Incorporated has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; Parion Sciences, Inc.; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Merck KGaA; and Janssen Pharmaceuticals, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
(Summary) (Company) (Chart)
(Summary) (Company) (Chart)
| 29 October 2017 Price $150.11 1yr Target $179.56 Analysts 25 Dividend $0.00 Payout Ratio 0.00% 1yr Cap Gain 19.61% Yield 0.00% 1yr Tot Return 19.61% P/E 145.31 PEG 2.13 Beta 1.67 | EPS (ttm) $1.03 EPS next yr $3.08 Forward P/E 48.80 EPS next 5yr 68.07% 1yr Price Support $209.65 Market Cap $37.84 Bil Revenues $2.13 Bil Earnings $259.50 Mil Profit Margin 12.15% Quick Ratio 3.50 Current Ratio 3.50 Debt/Equity 0.34 | 1yr RevGR 64.92% 3yr RevGR 11.88% 5yr RevGR 3.83% 1yr EarnGR --- 3yr EarnGR --- 5yr EarnGR --- 1yr DivGR --- 3yr DivGR --- 5yr DivGR --- ROA 8.80% ROE 19.40% |
RSS Feed
